Literature DB >> 17627034

Investigation of RNA interference to suppress expression of full-length and fragment human huntingtin.

Devin S Gary1, Abigail Davidson, Olivier Milhavet, Hilda Slunt, David R Borchelt.   

Abstract

The use of RNA interference (RNAi) to suppress the expression of genes has drastically improved the ability to examine gene function and is now being considered as a therapeutic approach for many diseases including genetic forms of neurodegenerative disease. Recently, research has focused on RNAi for the treatment of Huntington's and other polyglutamine diseases. In this work we explored the efficacy and specificity of short hairpin RNAs to target human huntingtin mRNA. We found two sequences that are specific for, and efficiently suppress human huntingtin mRNA. Mouse cell lines that stably harbored human short hairpin RNA constructs specifically inhibited the expression of human huntingtin supplied by transfected expression plasmids. However, these same constructs were unable to stably suppress endogenous human huntingtin when stably transfected into human 293 cells, despite effectively knocking down expression of huntingtin in transient transfection. These results demonstrate the efficacy and specificity of RNAi as a tool to target human huntingtin in RNAi-based therapies but point toward potential problems, possibly cell-type specific, regarding stable suppression of human huntingtin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627034     DOI: 10.1007/bf02685888

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  23 in total

Review 1.  Post-transcriptional gene silencing by double-stranded RNA.

Authors:  S M Hammond; A A Caudy; G J Hannon
Journal:  Nat Rev Genet       Date:  2001-02       Impact factor: 53.242

2.  Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.

Authors:  A Yamamoto; J J Lucas; R Hen
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

3.  Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells.

Authors:  Patrick J Paddison; Amy A Caudy; Emily Bernstein; Gregory J Hannon; Douglas S Conklin
Journal:  Genes Dev       Date:  2002-04-15       Impact factor: 11.361

4.  Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells.

Authors:  Gerry Shaw; Silas Morse; Miguel Ararat; Frank L Graham
Journal:  FASEB J       Date:  2002-04-10       Impact factor: 5.191

5.  Short interfering RNA confers intracellular antiviral immunity in human cells.

Authors:  Leonid Gitlin; Sveta Karelsky; Raul Andino
Journal:  Nature       Date:  2002-06-26       Impact factor: 49.962

6.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Authors:  Scott Q Harper; Patrick D Staber; Xiaohua He; Steven L Eliason; Inês H Martins; Qinwen Mao; Linda Yang; Robert M Kotin; Henry L Paulson; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-05       Impact factor: 11.205

7.  Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways.

Authors:  Dianne S Schwarz; György Hutvágner; Benjamin Haley; Phillip D Zamore
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

8.  Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.

Authors:  Edgardo Rodriguez-Lebron; Eileen M Denovan-Wright; Kevin Nash; Alfred S Lewin; Ronald J Mandel
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

9.  RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells.

Authors:  Jenn-Yah Yu; Stacy L DeRuiter; David L Turner
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-23       Impact factor: 11.205

10.  siRNA-mediated gene silencing in vitro and in vivo.

Authors:  Haibin Xia; Qinwen Mao; Henry L Paulson; Beverly L Davidson
Journal:  Nat Biotechnol       Date:  2002-09-16       Impact factor: 54.908

View more
  2 in total

Review 1.  Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics.

Authors:  Marc S Weinberg; Matthew J A Wood
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

2.  Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing.

Authors:  Karine Cambon; Virginie Zimmer; Sylvain Martineau; Marie-Claude Gaillard; Margot Jarrige; Aurore Bugi; Jana Miniarikova; Maria Rey; Raymonde Hassig; Noelle Dufour; Gwenaelle Auregan; Philippe Hantraye; Anselme L Perrier; Nicole Déglon
Journal:  Mol Ther Methods Clin Dev       Date:  2017-05-11       Impact factor: 6.698

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.